Evidence map›Paper›PMID 42502704›Full record

ArticleBone reports2026

Taylor deVet, Anthony Helou, Sara Checa, Alexander Rack, Ina Kramer, Fabian Wilde, Paul Zaslansky, Bettina M Willie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Taylor deVetDepartment of Biomedical Engineering, McGill University, Montreal, Canada.
Anthony HelouResearch Centre, Shriners Hospitals for Children, Montreal, Canada.
Sara ChecaInstitute of Biomechanics, Hamburg University of Technology, Hamburg, Germany.
Alexander RackESRF - The European Synchrotron, Grenoble, France.
Ina KramerNovartis Biomedical Research, Basel, Switzerland.
Fabian WildeHelmholtz-Zentrum Geesthacht, 21502, Geesthacht, Germany.
Paul ZaslanskyDepartment for Operative, Preventive and Pediatric Dentistry, Charité-Universitätsmedizin, Berlin, Germany.
Bettina M WillieDepartment of Biomedical Engineering, McGill University, Montreal, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerostin neutralizing antibody is an approved anabolic drug used to increase bone mass. Numerous preclinical studies examined bone mass and microstructural changes in mice receiving sclerostin neutralizing antibodies or mice lacking sclerostin, such as

Indexed as

AgingBone vascular porosityFracture healingLacunar propertiesSclerostin neutralizing antibodySost knockoutSynchrotron tomography

Identifiers

PMID42502704
PMCPMC13400213

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.